{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:20:42Z","timestamp":1771464042920,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2022 Fiscal Year Japan Agency for Medical Research and Development (AMED) Grant for the Project for Babies and Infants in Research of Health and Development to Adolescents and Young Adults","award":["JP22gk0110059"],"award-info":[{"award-number":["JP22gk0110059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertensive disorders of pregnancy lead to a critically ill maternal\/fetal state due to maternal organ failure and fetal dysfunction related to placental abruption or impaired placental circulation. No treatment with established efficacy for hypertensive disorders of pregnancy is currently available, and delivery is the only definitive treatment. This article describes the study protocol for a trial that aims to evaluate whether early pravastatin treatment is effective in preventing hypertensive disorders of pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized, open-label, parallel-group, three-arm trial will be conducted with aspirin administered as the baseline treatment across all groups. Pregnant women with a history of hypertensive disorders of pregnancy who are at high risk of developing hypertensive disorders of pregnancy will be recruited from four recruitment sites in Japan. The three interventions of the study comprise oral pravastatin 5\u00a0mg once daily with oral bayaspirin 100\u00a0mg once daily, oral pravastatin 10\u00a0mg once daily with oral bayaspirin 100\u00a0mg once daily, and oral bayaspirin 100\u00a0mg once daily alone. The primary outcome measure is the incidence of hypertension during pregnancy. The secondary outcome measures include incidence rates of preeclampsia and gestational hypertension, maternal serum soluble fms-like tyrosine kinase-1\/placental growth factor ratio, as well as soluble fms-like tyrosine kinase-1 and placental growth factor levels, whether the mother is proteinuric, placental weight, umbilical cord blood lipid profile, the incidence of hypertensive disorders of pregnancy-related complications (placental abruption, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia), week at diagnosis of hypertensive disorders of pregnancy, incidence of severe hypertensive disorders of pregnancy, and neonatal outcomes (birth weight, percentage of small for gestational age neonates, neonatal intensive care unit admission rate, and auditory brainstem response).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results of this study are expected to have wide-ranging implications given the effects of hypertensive disorders of pregnancy on long-term maternal and child health, as well as health economics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Japan Registry of Clinical Trials (Trial ID: jRCTs031230067; registered May 11, 2023;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs031230067\" ext-link-type=\"uri\">https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCTs031230067<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09136-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:29:27Z","timestamp":1762961367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Keiichi","family":"Kumasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kashiwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nagamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"9136_CR1","doi-asserted-by":"publisher","unstructured":"Takagi K, Nakamoto O, Wanatabe K, Tanaka K, Matsubara K, Kawabata I, et al. A review of the best practice Guide 2021 for the diagnosis and management of hypertensive disorders of pregnancy (HDP). Hypertens Res Pregnancy. 2022;10:57\u201373. https:\/\/doi.org\/10.14390\/jsshp.10.57.","DOI":"10.14390\/jsshp.10.57"},{"key":"9136_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.bpobgyn.2011.01.006","volume":"25","author":"JA Hutcheon","year":"2011","unstructured":"Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391\u2013403. https:\/\/doi.org\/10.1016\/j.bpobgyn.2011.01.006.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"9136_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, O\u2019Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1704559.","journal-title":"N Engl J Med"},{"key":"9136_CR4","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3390\/nu12103203","volume":"12","author":"J Kim","year":"2020","unstructured":"Kim J, Hoang T, Kim JM, Bu SY, Choi JH, Park E, et al. All-cause mortality and cardiovascular death between statins and omega-3 supplementation: a meta-analysis and network meta-analysis from 55 randomized controlled trials. Nutrients. 2020;12:3203. https:\/\/doi.org\/10.3390\/nu12103203.","journal-title":"Nutrients"},{"key":"9136_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","volume":"210","author":"HG Yebyo","year":"2019","unstructured":"Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18\u201328. https:\/\/doi.org\/10.1016\/j.ahj.2018.12.007.","journal-title":"Am Heart J"},{"key":"9136_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100980","volume":"3","author":"LJ Shaw","year":"2024","unstructured":"Shaw LJ, Patel K, Lala-Trindade A, Feltovich H, Vieira L, Kontorovich A, et al. Pathophysiology of preeclampsia-induced vascular dysfunction and implications for subclinical myocardial damage and heart failure. JACC: Advances. 2024;3:100980. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100980.","journal-title":"JACC: Advances"},{"key":"9136_CR7","doi-asserted-by":"publisher","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","volume":"226","author":"DD Smith","year":"2022","unstructured":"Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. 2022;226:S1171\u201381. https:\/\/doi.org\/10.1016\/j.ajog.2020.08.040.","journal-title":"Am J Obstet Gynecol"},{"key":"9136_CR8","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.3390\/ijms25147569","volume":"25","author":"J Torres-Torres","year":"2024","unstructured":"Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, Borboa-Olivares H, Estrada-Gutierrez G, Acevedo-Gallegos S, et al. A narrative review on the pathophysiology of preeclampsia. Int J Mol Sci. 2024;25:7569. https:\/\/doi.org\/10.3390\/ijms25147569.","journal-title":"Int J Mol Sci"},{"key":"9136_CR9","first-page":"185","volume":"33","author":"K Kumasawa","year":"2025","unstructured":"Kumasawa K. Potential of pravastatin for the prevention and treatment of preeclampsia. Thai J Obstet Gynaecol. 2025;33:185\u201394.","journal-title":"Thai J Obstet Gynaecol"},{"key":"9136_CR10","doi-asserted-by":"publisher","first-page":"S1157","DOI":"10.1016\/j.ajog.2020.09.014","volume":"226","author":"S Tong","year":"2022","unstructured":"Tong S, Kaitu\u2019u-Lino TJ, Hastie R, Brownfoot F, Cluver C, Hannan N. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2022;226:S1157\u201370. https:\/\/doi.org\/10.1016\/j.ajog.2020.09.014.","journal-title":"Am J Obstet Gynecol"},{"key":"9136_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1073\/pnas.1011293108","volume":"108","author":"K Kumasawa","year":"2011","unstructured":"Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108:1451\u20135. https:\/\/doi.org\/10.1073\/pnas.1011293108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9136_CR12","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1007\/s43032-024-01611-x","volume":"31","author":"M Kanda","year":"2024","unstructured":"Kanda M, Kumasawa K, Nemoto K, Miyatake R, Inaba K, Sayama S, et al. The effects of low concentrations of pravastatin on placental cells. Reprod Sci. 2024;31:3139\u201347. https:\/\/doi.org\/10.1007\/s43032-024-01611-x.","journal-title":"Reprod Sci"},{"key":"9136_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1076372","volume":"9","author":"B M\u00e9sz\u00e1ros","year":"2023","unstructured":"M\u00e9sz\u00e1ros B, Veres DS, Nagyist\u00f3k L, Somogyi A, Rosta K, Herold Z, et al. Pravastatin in preeclampsia: a meta-analysis and systematic review. Front Med Lausanne. 2023;9:1076372. https:\/\/doi.org\/10.3389\/fmed.2022.1076372.","journal-title":"Front Med Lausanne"},{"key":"9136_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.semperi.2014.08.019","volume":"38","author":"KL Cleary","year":"2014","unstructured":"Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol. 2014;38:523\u20137. https:\/\/doi.org\/10.1053\/j.semperi.2014.08.019.","journal-title":"Semin Perinatol"},{"key":"9136_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.09.010","volume":"336","author":"A Vahedian-Azimi","year":"2021","unstructured":"Vahedian-Azimi A, Bianconi V, Makvandi S, Banach M, Mohammadi SM, Pirro M, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. 2021;336:1\u201311. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.010.","journal-title":"Atherosclerosis"},{"key":"9136_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/jog.14295","volume":"46","author":"K Kumasawa","year":"2020","unstructured":"Kumasawa K, Iriyama T, Nagamatsu T, Osuga Y, Fujii T. Pravastatin for preeclampsia: from animal to human. J Obstet Gynaecol Res. 2020;46:1255\u201362. https:\/\/doi.org\/10.1111\/jog.14295.","journal-title":"J Obstet Gynaecol Res"},{"key":"9136_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1035","volume":"350","author":"BT Bateman","year":"2015","unstructured":"Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035. https:\/\/doi.org\/10.1136\/bmj.h1035.","journal-title":"BMJ"},{"key":"9136_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S1701-2163(15)30565-X","volume":"36","author":"J Zarek","year":"2014","unstructured":"Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36:506\u20139. https:\/\/doi.org\/10.1016\/S1701-2163(15)30565-X.","journal-title":"J Obstet Gynaecol Can"},{"key":"9136_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/a-1673-5603","volume":"41","author":"MIA Akbar","year":"2024","unstructured":"Akbar MIA, Yosediputra A, Pratama RE, Fadhilah NL, Sulistyowati S, Amani FZ, et al. Inovasia study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1\/PlGF levels. Am J Perinatol. 2024;41:300\u20139. https:\/\/doi.org\/10.1055\/a-1673-5603.","journal-title":"Am J Perinatol"},{"key":"9136_CR20","doi-asserted-by":"publisher","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","volume":"214","author":"MM Costantine","year":"2016","unstructured":"Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214:720.e1-720.e17. https:\/\/doi.org\/10.1016\/j.ajog.2015.12.038.","journal-title":"Am J Obstet Gynecol"},{"key":"9136_CR21","doi-asserted-by":"publisher","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","volume":"225","author":"MM Costantine","year":"2021","unstructured":"Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021;225:666.e1-666.e15. https:\/\/doi.org\/10.1016\/j.ajog.2021.05.018.","journal-title":"Am J Obstet Gynecol"},{"key":"9136_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"key":"9136_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","volume":"72","author":"MA Brown","year":"2018","unstructured":"Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24\u201343. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10803.","journal-title":"Hypertension"},{"key":"9136_CR24","unstructured":"Levy D, Blood E. Minimization: testing a dynamic randomization algorithm. 2004. https:\/\/www.lexjansen.com\/nesug\/nesug04\/ap\/ap07.pdf. Accessed 10 March 2025."},{"key":"9136_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1414838.","journal-title":"N Engl J Med"},{"key":"9136_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","volume":"74","author":"X Bian","year":"2019","unstructured":"Bian X, Biswas A, Huang X, Lee KJ, Li TK, Masuyama H, et al. Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia. Hypertension. 2019;74:164\u201372. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.12760.","journal-title":"Hypertension"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09136-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:29:28Z","timestamp":1762961368000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9136"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09136-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Tokyo Clinical Research Review Board (Approval No. 2022534SP) in accordance with the ethical standards of the University of Tokyo Hospital and the Declaration of Helsinki. Written informed consent will be obtained from all the participants before their inclusion in the study. The participants will be provided with detailed information regarding the purpose, procedures, potential risks, and benefits of the study, and their voluntary participation and right to withdraw at any time will be emphasized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"499"}}